Recombinant Protein Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Recombinant Protein Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type Recombinant DNA Recombinant RNA Segment by Application Pharmaceutical Industry Others By Company Novo Nordisk Amgen Sanofi Eli Lilly Merck Serono Ortho Biotech Roche Kyowa Hakko Kirin Pharmingen Abcam GenSci SL PHARM Dongbao Pharm Ankebio NCPC Heng Rui By Region North America U.S. Canada Europe Germany France U.K. Italy Russia Asia-Pacific China Japan South Korea India Australia Taiwan Indonesia Thailand Malaysia Philippines Vietnam Latin America Mexico Brazil Argentina Middle East & Africa Turkey Saudi Arabia U.A.E
1 Study Coverage 1.1 Recombinant Protein Drugs Product Introduction 1.2 Market by Type 1.2.1 Global Recombinant Protein Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 1.2.2 Recombinant DNA 1.2.3 Recombinant RNA 1.3 Market by Application 1.3.1 Global Recombinant Protein Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 1.3.2 Pharmaceutical Industry 1.3.3 Others 1.4 Study Objectives 1.5 Years Considered 2 Executive Summary 2.1 Global Recombinant Protein Drugs Sales Estimates and Forecasts 2017-2028 2.2 Global Recombinant Protein Drugs Revenue Estimates and Forecasts 2017-2028 2.3 Global Recombinant Protein Drugs Revenue by Region: 2017 VS 2021 VS 2028 2.4 Global Recombinant Protein Drugs Sales by Region 2.4.1 Global Recombinant Protein Drugs Sales by Region (2017-2022) 2.4.2 Global Sales Recombinant Protein Drugs by Region (2023-2028) 2.5 Global Recombinant Protein Drugs Revenue by Region 2.5.1 Global Recombinant Protein Drugs Revenue by Region (2017-2022) 2.5.2 Global Recombinant Protein Drugs Revenue by Region (2023-2028) 2.6 North America 2.7 Europe 2.8 Asia-Pacific 2.9 Latin America 2.10 Middle East & Africa 3 Competition by Manufacturers 3.1 Global Recombinant Protein Drugs Sales by Manufacturers 3.1.1 Global Top Recombinant Protein Drugs Manufacturers by Sales (2017-2022) 3.1.2 Global Recombinant Protein Drugs Sales Market Share by Manufacturers (2017-2022) 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Recombinant Protein Drugs in 2021 3.2 Global Recombinant Protein Drugs Revenue by Manufacturers 3.2.1 Global Recombinant Protein Drugs Revenue by Manufacturers (2017-2022) 3.2.2 Global Recombinant Protein Drugs Revenue Market Share by Manufacturers (2017-2022) 3.2.3 Global Top 10 and Top 5 Companies by Recombinant Protein Drugs Revenue in 2021 3.3 Global Recombinant Protein Drugs Sales Price by Manufacturers (2017-2022) 3.4 Analysis of Competitive Landscape 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Recombinant Protein Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.4.3 Global Recombinant Protein Drugs Manufacturers Geographical Distribution 3.5 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type 4.1 Global Recombinant Protein Drugs Sales by Type 4.1.1 Global Recombinant Protein Drugs Historical Sales by Type (2017-2022) 4.1.2 Global Recombinant Protein Drugs Forecasted Sales by Type (2023-2028) 4.1.3 Global Recombinant Protein Drugs Sales Market Share by Type (2017-2028) 4.2 Global Recombinant Protein Drugs Revenue by Type 4.2.1 Global Recombinant Protein Drugs Historical Revenue by Type (2017-2022) 4.2.2 Global Recombinant Protein Drugs Forecasted Revenue by Type (2023-2028) 4.2.3 Global Recombinant Protein Drugs Revenue Market Share by Type (2017-2028) 4.3 Global Recombinant Protein Drugs Price by Type 4.3.1 Global Recombinant Protein Drugs Price by Type (2017-2022) 4.3.2 Global Recombinant Protein Drugs Price Forecast by Type (2023-2028) 5 Market Size by Application 5.1 Global Recombinant Protein Drugs Sales by Application 5.1.1 Global Recombinant Protein Drugs Historical Sales by Application (2017-2022) 5.1.2 Global Recombinant Protein Drugs Forecasted Sales by Application (2023-2028) 5.1.3 Global Recombinant Protein Drugs Sales Market Share by Application (2017-2028) 5.2 Global Recombinant Protein Drugs Revenue by Application 5.2.1 Global Recombinant Protein Drugs Historical Revenue by Application (2017-2022) 5.2.2 Global Recombinant Protein Drugs Forecasted Revenue by Application (2023-2028) 5.2.3 Global Recombinant Protein Drugs Revenue Market Share by Application (2017-2028) 5.3 Global Recombinant Protein Drugs Price by Application 5.3.1 Global Recombinant Protein Drugs Price by Application (2017-2022) 5.3.2 Global Recombinant Protein Drugs Price Forecast by Application (2023-2028) 6 North America 6.1 North America Recombinant Protein Drugs Market Size by Type 6.1.1 North America Recombinant Protein Drugs Sales by Type (2017-2028) 6.1.2 North America Recombinant Protein Drugs Revenue by Type (2017-2028) 6.2 North America Recombinant Protein Drugs Market Size by Application 6.2.1 North America Recombinant Protein Drugs Sales by Application (2017-2028) 6.2.2 North America Recombinant Protein Drugs Revenue by Application (2017-2028) 6.3 North America Recombinant Protein Drugs Market Size by Country 6.3.1 North America Recombinant Protein Drugs Sales by Country (2017-2028) 6.3.2 North America Recombinant Protein Drugs Revenue by Country (2017-2028) 6.3.3 U.S. 6.3.4 Canada 7 Europe 7.1 Europe Recombinant Protein Drugs Market Size by Type 7.1.1 Europe Recombinant Protein Drugs Sales by Type (2017-2028) 7.1.2 Europe Recombinant Protein Drugs Revenue by Type (2017-2028) 7.2 Europe Recombinant Protein Drugs Market Size by Application 7.2.1 Europe Recombinant Protein Drugs Sales by Application (2017-2028) 7.2.2 Europe Recombinant Protein Drugs Revenue by Application (2017-2028) 7.3 Europe Recombinant Protein Drugs Market Size by Country 7.3.1 Europe Recombinant Protein Drugs Sales by Country (2017-2028) 7.3.2 Europe Recombinant Protein Drugs Revenue by Country (2017-2028) 7.3.3 Germany 7.3.4 France 7.3.5 U.K. 7.3.6 Italy 7.3.7 Russia 8 Asia Pacific 8.1 Asia Pacific Recombinant Protein Drugs Market Size by Type 8.1.1 Asia Pacific Recombinant Protein Drugs Sales by Type (2017-2028) 8.1.2 Asia Pacific Recombinant Protein Drugs Revenue by Type (2017-2028) 8.2 Asia Pacific Recombinant Protein Drugs Market Size by Application 8.2.1 Asia Pacific Recombinant Protein Drugs Sales by Application (2017-2028) 8.2.2 Asia Pacific Recombinant Protein Drugs Revenue by Application (2017-2028) 8.3 Asia Pacific Recombinant Protein Drugs Market Size by Region 8.3.1 Asia Pacific Recombinant Protein Drugs Sales by Region (2017-2028) 8.3.2 Asia Pacific Recombinant Protein Drugs Revenue by Region (2017-2028) 8.3.3 China 8.3.4 Japan 8.3.5 South Korea 8.3.6 India 8.3.7 Australia 8.3.8 Taiwan 8.3.9 Indonesia 8.3.10 Thailand 8.3.11 Malaysia 8.3.12 Philippines 9 Latin America 9.1 Latin America Recombinant Protein Drugs Market Size by Type 9.1.1 Latin America Recombinant Protein Drugs Sales by Type (2017-2028) 9.1.2 Latin America Recombinant Protein Drugs Revenue by Type (2017-2028) 9.2 Latin America Recombinant Protein Drugs Market Size by Application 9.2.1 Latin America Recombinant Protein Drugs Sales by Application (2017-2028) 9.2.2 Latin America Recombinant Protein Drugs Revenue by Application (2017-2028) 9.3 Latin America Recombinant Protein Drugs Market Size by Country 9.3.1 Latin America Recombinant Protein Drugs Sales by Country (2017-2028) 9.3.2 Latin America Recombinant Protein Drugs Revenue by Country (2017-2028) 9.3.3 Mexico 9.3.4 Brazil 9.3.5 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Recombinant Protein Drugs Market Size by Type 10.1.1 Middle East and Africa Recombinant Protein Drugs Sales by Type (2017-2028) 10.1.2 Middle East and Africa Recombinant Protein Drugs Revenue by Type (2017-2028) 10.2 Middle East and Africa Recombinant Protein Drugs Market Size by Application 10.2.1 Middle East and Africa Recombinant Protein Drugs Sales by Application (2017-2028) 10.2.2 Middle East and Africa Recombinant Protein Drugs Revenue by Application (2017-2028) 10.3 Middle East and Africa Recombinant Protein Drugs Market Size by Country 10.3.1 Middle East and Africa Recombinant Protein Drugs Sales by Country (2017-2028) 10.3.2 Middle East and Africa Recombinant Protein Drugs Revenue by Country (2017-2028) 10.3.3 Turkey 10.3.4 Saudi Arabia 11 Company Profiles 11.1 Novo Nordisk 11.1.1 Novo Nordisk Corporation Information 11.1.2 Novo Nordisk Overview 11.1.3 Novo Nordisk Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.1.4 Novo Nordisk Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.1.5 Novo Nordisk Recent Developments 11.2 Amgen 11.2.1 Amgen Corporation Information 11.2.2 Amgen Overview 11.2.3 Amgen Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.2.4 Amgen Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.2.5 Amgen Recent Developments 11.3 Sanofi 11.3.1 Sanofi Corporation Information 11.3.2 Sanofi Overview 11.3.3 Sanofi Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.3.4 Sanofi Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.3.5 Sanofi Recent Developments 11.4 Eli Lilly 11.4.1 Eli Lilly Corporation Information 11.4.2 Eli Lilly Overview 11.4.3 Eli Lilly Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.4.4 Eli Lilly Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.4.5 Eli Lilly Recent Developments 11.5 Merck Serono 11.5.1 Merck Serono Corporation Information 11.5.2 Merck Serono Overview 11.5.3 Merck Serono Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.5.4 Merck Serono Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.5.5 Merck Serono Recent Developments 11.6 Ortho Biotech 11.6.1 Ortho Biotech Corporation Information 11.6.2 Ortho Biotech Overview 11.6.3 Ortho Biotech Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.6.4 Ortho Biotech Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.6.5 Ortho Biotech Recent Developments 11.7 Roche 11.7.1 Roche Corporation Information 11.7.2 Roche Overview 11.7.3 Roche Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.7.4 Roche Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.7.5 Roche Recent Developments 11.8 Kyowa Hakko Kirin 11.8.1 Kyowa Hakko Kirin Corporation Information 11.8.2 Kyowa Hakko Kirin Overview 11.8.3 Kyowa Hakko Kirin Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.8.4 Kyowa Hakko Kirin Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.8.5 Kyowa Hakko Kirin Recent Developments 11.9 Pharmingen 11.9.1 Pharmingen Corporation Information 11.9.2 Pharmingen Overview 11.9.3 Pharmingen Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.9.4 Pharmingen Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.9.5 Pharmingen Recent Developments 11.10 Abcam 11.10.1 Abcam Corporation Information 11.10.2 Abcam Overview 11.10.3 Abcam Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.10.4 Abcam Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.10.5 Abcam Recent Developments 11.11 GenSci 11.11.1 GenSci Corporation Information 11.11.2 GenSci Overview 11.11.3 GenSci Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.11.4 GenSci Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.11.5 GenSci Recent Developments 11.12 SL PHARM 11.12.1 SL PHARM Corporation Information 11.12.2 SL PHARM Overview 11.12.3 SL PHARM Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.12.4 SL PHARM Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.12.5 SL PHARM Recent Developments 11.13 Dongbao Pharm 11.13.1 Dongbao Pharm Corporation Information 11.13.2 Dongbao Pharm Overview 11.13.3 Dongbao Pharm Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.13.4 Dongbao Pharm Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.13.5 Dongbao Pharm Recent Developments 11.14 Ankebio 11.14.1 Ankebio Corporation Information 11.14.2 Ankebio Overview 11.14.3 Ankebio Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.14.4 Ankebio Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.14.5 Ankebio Recent Developments 11.15 NCPC 11.15.1 NCPC Corporation Information 11.15.2 NCPC Overview 11.15.3 NCPC Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.15.4 NCPC Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.15.5 NCPC Recent Developments 11.16 Heng Rui 11.16.1 Heng Rui Corporation Information 11.16.2 Heng Rui Overview 11.16.3 Heng Rui Recombinant Protein Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.16.4 Heng Rui Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.16.5 Heng Rui Recent Developments 12 Industry Chain and Sales Channels Analysis 12.1 Recombinant Protein Drugs Industry Chain Analysis 12.2 Recombinant Protein Drugs Key Raw Materials 12.2.1 Key Raw Materials 12.2.2 Raw Materials Key Suppliers 12.3 Recombinant Protein Drugs Production Mode & Process 12.4 Recombinant Protein Drugs Sales and Marketing 12.4.1 Recombinant Protein Drugs Sales Channels 12.4.2 Recombinant Protein Drugs Distributors 12.5 Recombinant Protein Drugs Customers 13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis 13.1 Recombinant Protein Drugs Industry Trends 13.2 Recombinant Protein Drugs Market Drivers 13.3 Recombinant Protein Drugs Market Challenges 13.4 Recombinant Protein Drugs Market Restraints 14 Key Findings in The Global Recombinant Protein Drugs Study 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Author Details 15.3 Disclaimer
List of Tables Table 1. Global Recombinant Protein Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million) Table 2. Major Manufacturers of Recombinant DNA Table 3. Major Manufacturers of Recombinant RNA Table 4. Global Recombinant Protein Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million) Table 5. Global Recombinant Protein Drugs Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million) Table 6. Global Recombinant Protein Drugs Sales by Region (2017-2022) & (K Doses) Table 7. Global Recombinant Protein Drugs Sales Market Share by Region (2017-2022) Table 8. Global Recombinant Protein Drugs Sales by Region (2023-2028) & (K Doses) Table 9. Global Recombinant Protein Drugs Sales Market Share by Region (2023-2028) Table 10. Global Recombinant Protein Drugs Revenue by Region (2017-2022) & (US$ Million) Table 11. Global Recombinant Protein Drugs Revenue Market Share by Region (2017-2022) Table 12. Global Recombinant Protein Drugs Revenue by Region (2023-2028) & (US$ Million) Table 13. Global Recombinant Protein Drugs Revenue Market Share by Region (2023-2028) Table 14. Global Recombinant Protein Drugs Sales by Manufacturers (2017-2022) & (K Doses) Table 15. Global Recombinant Protein Drugs Sales Share by Manufacturers (2017-2022) Table 16. Global Recombinant Protein Drugs Revenue by Manufacturers (2017-2022) & (US$ Million) Table 17. Global Recombinant Protein Drugs Revenue Share by Manufacturers (2017-2022) Table 18. Recombinant Protein Drugs Price by Manufacturers (2017-2022) &(USD/Dose) Table 19. Global Recombinant Protein Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) Table 20. Global Recombinant Protein Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Protein Drugs as of 2021) Table 21. Recombinant Protein Drugs Manufacturing Base Distribution and Headquarters Table 22. Manufacturers Recombinant Protein Drugs Product Offered Table 23. Date of Manufacturers Enter into Recombinant Protein Drugs Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Recombinant Protein Drugs Sales by Type (2017-2022) & (K Doses) Table 26. Global Recombinant Protein Drugs Sales by Type (2023-2028) & (K Doses) Table 27. Global Recombinant Protein Drugs Sales Share by Type (2017-2022) Table 28. Global Recombinant Protein Drugs Sales Share by Type (2023-2028) Table 29. Global Recombinant Protein Drugs Revenue by Type (2017-2022) & (US$ Million) Table 30. Global Recombinant Protein Drugs Revenue by Type (2023-2028) & (US$ Million) Table 31. Global Recombinant Protein Drugs Revenue Share by Type (2017-2022) Table 32. Global Recombinant Protein Drugs Revenue Share by Type (2023-2028) Table 33. Recombinant Protein Drugs Price by Type (2017-2022) & (USD/Dose) Table 34. Global Recombinant Protein Drugs Price Forecast by Type (2023-2028) & (USD/Dose) Table 35. Global Recombinant Protein Drugs Sales by Application (2017-2022) & (K Doses) Table 36. Global Recombinant Protein Drugs Sales by Application (2023-2028) & (K Doses) Table 37. Global Recombinant Protein Drugs Sales Share by Application (2017-2022) Table 38. Global Recombinant Protein Drugs Sales Share by Application (2023-2028) Table 39. Global Recombinant Protein Drugs Revenue by Application (2017-2022) & (US$ Million) Table 40. Global Recombinant Protein Drugs Revenue by Application (2023-2028) & (US$ Million) Table 41. Global Recombinant Protein Drugs Revenue Share by Application (2017-2022) Table 42. Global Recombinant Protein Drugs Revenue Share by Application (2023-2028) Table 43. Recombinant Protein Drugs Price by Application (2017-2022) & (USD/Dose) Table 44. Global Recombinant Protein Drugs Price Forecast by Application (2023-2028) & (USD/Dose) Table 45. North America Recombinant Protein Drugs Sales by Type (2017-2022) & (K Doses) Table 46. North America Recombinant Protein Drugs Sales by Type (2023-2028) & (K Doses) Table 47. North America Recombinant Protein Drugs Revenue by Type (2017-2022) & (US$ Million) Table 48. North America Recombinant Protein Drugs Revenue by Type (2023-2028) & (US$ Million) Table 49. North America Recombinant Protein Drugs Sales by Application (2017-2022) & (K Doses) Table 50. North America Recombinant Protein Drugs Sales by Application (2023-2028) & (K Doses) Table 51. North America Recombinant Protein Drugs Revenue by Application (2017-2022) & (US$ Million) Table 52. North America Recombinant Protein Drugs Revenue by Application (2023-2028) & (US$ Million) Table 53. North America Recombinant Protein Drugs Sales by Country (2017-2022) & (K Doses) Table 54. North America Recombinant Protein Drugs Sales by Country (2023-2028) & (K Doses) Table 55. North America Recombinant Protein Drugs Revenue by Country (2017-2022) & (US$ Million) Table 56. North America Recombinant Protein Drugs Revenue by Country (2023-2028) & (US$ Million) Table 57. Europe Recombinant Protein Drugs Sales by Type (2017-2022) & (K Doses) Table 58. Europe Recombinant Protein Drugs Sales by Type (2023-2028) & (K Doses) Table 59. Europe Recombinant Protein Drugs Revenue by Type (2017-2022) & (US$ Million) Table 60. Europe Recombinant Protein Drugs Revenue by Type (2023-2028) & (US$ Million) Table 61. Europe Recombinant Protein Drugs Sales by Application (2017-2022) & (K Doses) Table 62. Europe Recombinant Protein Drugs Sales by Application (2023-2028) & (K Doses) Table 63. Europe Recombinant Protein Drugs Revenue by Application (2017-2022) & (US$ Million) Table 64. Europe Recombinant Protein Drugs Revenue by Application (2023-2028) & (US$ Million) Table 65. Europe Recombinant Protein Drugs Sales by Country (2017-2022) & (K Doses) Table 66. Europe Recombinant Protein Drugs Sales by Country (2023-2028) & (K Doses) Table 67. Europe Recombinant Protein Drugs Revenue by Country (2017-2022) & (US$ Million) Table 68. Europe Recombinant Protein Drugs Revenue by Country (2023-2028) & (US$ Million) Table 69. Asia Pacific Recombinant Protein Drugs Sales by Type (2017-2022) & (K Doses) Table 70. Asia Pacific Recombinant Protein Drugs Sales by Type (2023-2028) & (K Doses) Table 71. Asia Pacific Recombinant Protein Drugs Revenue by Type (2017-2022) & (US$ Million) Table 72. Asia Pacific Recombinant Protein Drugs Revenue by Type (2023-2028) & (US$ Million) Table 73. Asia Pacific Recombinant Protein Drugs Sales by Application (2017-2022) & (K Doses) Table 74. Asia Pacific Recombinant Protein Drugs Sales by Application (2023-2028) & (K Doses) Table 75. Asia Pacific Recombinant Protein Drugs Revenue by Application (2017-2022) & (US$ Million) Table 76. Asia Pacific Recombinant Protein Drugs Revenue by Application (2023-2028) & (US$ Million) Table 77. Asia Pacific Recombinant Protein Drugs Sales by Region (2017-2022) & (K Doses) Table 78. Asia Pacific Recombinant Protein Drugs Sales by Region (2023-2028) & (K Doses) Table 79. Asia Pacific Recombinant Protein Drugs Revenue by Region (2017-2022) & (US$ Million) Table 80. Asia Pacific Recombinant Protein Drugs Revenue by Region (2023-2028) & (US$ Million) Table 81. Latin America Recombinant Protein Drugs Sales by Type (2017-2022) & (K Doses) Table 82. Latin America Recombinant Protein Drugs Sales by Type (2023-2028) & (K Doses) Table 83. Latin America Recombinant Protein Drugs Revenue by Type (2017-2022) & (US$ Million) Table 84. Latin America Recombinant Protein Drugs Revenue by Type (2023-2028) & (US$ Million) Table 85. Latin America Recombinant Protein Drugs Sales by Application (2017-2022) & (K Doses) Table 86. Latin America Recombinant Protein Drugs Sales by Application (2023-2028) & (K Doses) Table 87. Latin America Recombinant Protein Drugs Revenue by Application (2017-2022) & (US$ Million) Table 88. Latin America Recombinant Protein Drugs Revenue by Application (2023-2028) & (US$ Million) Table 89. Latin America Recombinant Protein Drugs Sales by Country (2017-2022) & (K Doses) Table 90. Latin America Recombinant Protein Drugs Sales by Country (2023-2028) & (K Doses) Table 91. Latin America Recombinant Protein Drugs Revenue by Country (2017-2022) & (US$ Million) Table 92. Latin America Recombinant Protein Drugs Revenue by Country (2023-2028) & (US$ Million) Table 93. Middle East and Africa Recombinant Protein Drugs Sales by Type (2017-2022) & (K Doses) Table 94. Middle East and Africa Recombinant Protein Drugs Sales by Type (2023-2028) & (K Doses) Table 95. Middle East and Africa Recombinant Protein Drugs Revenue by Type (2017-2022) & (US$ Million) Table 96. Middle East and Africa Recombinant Protein Drugs Revenue by Type (2023-2028) & (US$ Million) Table 97. Middle East and Africa Recombinant Protein Drugs Sales by Application (2017-2022) & (K Doses) Table 98. Middle East and Africa Recombinant Protein Drugs Sales by Application (2023-2028) & (K Doses) Table 99. Middle East and Africa Recombinant Protein Drugs Revenue by Application (2017-2022) & (US$ Million) Table 100. Middle East and Africa Recombinant Protein Drugs Revenue by Application (2023-2028) & (US$ Million) Table 101. Middle East and Africa Recombinant Protein Drugs Sales by Country (2017-2022) & (K Doses) Table 102. Middle East and Africa Recombinant Protein Drugs Sales by Country (2023-2028) & (K Doses) Table 103. Middle East and Africa Recombinant Protein Drugs Revenue by Country (2017-2022) & (US$ Million) Table 104. Middle East and Africa Recombinant Protein Drugs Revenue by Country (2023-2028) & (US$ Million) Table 105. Novo Nordisk Corporation Information Table 106. Novo Nordisk Description and Major Businesses Table 107. Novo Nordisk Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 108. Novo Nordisk Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 109. Novo Nordisk Recent Developments Table 110. Amgen Corporation Information Table 111. Amgen Description and Major Businesses Table 112. Amgen Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 113. Amgen Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 114. Amgen Recent Developments Table 115. Sanofi Corporation Information Table 116. Sanofi Description and Major Businesses Table 117. Sanofi Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 118. Sanofi Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 119. Sanofi Recent Developments Table 120. Eli Lilly Corporation Information Table 121. Eli Lilly Description and Major Businesses Table 122. Eli Lilly Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 123. Eli Lilly Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 124. Eli Lilly Recent Developments Table 125. Merck Serono Corporation Information Table 126. Merck Serono Description and Major Businesses Table 127. Merck Serono Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 128. Merck Serono Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 129. Merck Serono Recent Developments Table 130. Ortho Biotech Corporation Information Table 131. Ortho Biotech Description and Major Businesses Table 132. Ortho Biotech Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 133. Ortho Biotech Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 134. Ortho Biotech Recent Developments Table 135. Roche Corporation Information Table 136. Roche Description and Major Businesses Table 137. Roche Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 138. Roche Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 139. Roche Recent Developments Table 140. Kyowa Hakko Kirin Corporation Information Table 141. Kyowa Hakko Kirin Description and Major Businesses Table 142. Kyowa Hakko Kirin Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 143. Kyowa Hakko Kirin Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 144. Kyowa Hakko Kirin Recent Developments Table 145. Pharmingen Corporation Information Table 146. Pharmingen Description and Major Businesses Table 147. Pharmingen Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 148. Pharmingen Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 149. Pharmingen Recent Developments Table 150. Abcam Corporation Information Table 151. Abcam Description and Major Businesses Table 152. Abcam Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 153. Abcam Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 154. Abcam Recent Developments Table 155. GenSci Corporation Information Table 156. GenSci Description and Major Businesses Table 157. GenSci Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 158. GenSci Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 159. GenSci Recent Developments Table 160. SL PHARM Corporation Information Table 161. SL PHARM Description and Major Businesses Table 162. SL PHARM Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 163. SL PHARM Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 164. SL PHARM Recent Developments Table 165. Dongbao Pharm Corporation Information Table 166. Dongbao Pharm Description and Major Businesses Table 167. Dongbao Pharm Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 168. Dongbao Pharm Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 169. Dongbao Pharm Recent Developments Table 170. Ankebio Corporation Information Table 171. Ankebio Description and Major Businesses Table 172. Ankebio Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 173. Ankebio Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 174. Ankebio Recent Developments Table 175. NCPC Corporation Information Table 176. NCPC Description and Major Businesses Table 177. NCPC Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 178. NCPC Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 179. NCPC Recent Developments Table 180. Heng Rui Corporation Information Table 181. Heng Rui Description and Major Businesses Table 182. Heng Rui Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 183. Heng Rui Recombinant Protein Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 184. Heng Rui Recent Developments Table 185. Key Raw Materials Lists Table 186. Raw Materials Key Suppliers Lists Table 187. Recombinant Protein Drugs Distributors List Table 188. Recombinant Protein Drugs Customers List Table 189. Recombinant Protein Drugs Market Trends Table 190. Recombinant Protein Drugs Market Drivers Table 191. Recombinant Protein Drugs Market Challenges Table 192. Recombinant Protein Drugs Market Restraints Table 193. Research Programs/Design for This Report Table 194. Key Data Information from Secondary Sources Table 195. Key Data Information from Primary Sources List of Figures Figure 1. Recombinant Protein Drugs Product Picture Figure 3. Global Recombinant Protein Drugs Market Share by Type in 2021 & 2028 Figure 3. Recombinant DNA Product Picture Figure 4. Recombinant RNA Product Picture Figure 5. Global Recombinant Protein Drugs Market Share by Application in 2021 & 2028 Figure 6. Pharmaceutical Industry Figure 7. Others Figure 8. Recombinant Protein Drugs Report Years Considered Figure 9. Global Recombinant Protein Drugs Sales 2017-2028 (K Doses) Figure 10. Global Recombinant Protein Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 11. Global Recombinant Protein Drugs Revenue 2017-2028 (US$ Million) Figure 12. Global Recombinant Protein Drugs Revenue Market Share by Region in Percentage: 2021 Versus 2028 Figure 13. Global Recombinant Protein Drugs Sales Market Share by Region (2017-2022) Figure 14. Global Recombinant Protein Drugs Sales Market Share by Region (2023-2028) Figure 15. North America Recombinant Protein Drugs Sales YoY (2017-2028) & (K Doses) Figure 16. North America Recombinant Protein Drugs Revenue YoY (2017-2028) & (US$ Million) Figure 17. Europe Recombinant Protein Drugs Sales YoY (2017-2028) & (K Doses) Figure 18. Europe Recombinant Protein Drugs Revenue YoY (2017-2028) & (US$ Million) Figure 19. Asia-Pacific Recombinant Protein Drugs Sales YoY (2017-2028) & (K Doses) Figure 20. Asia-Pacific Recombinant Protein Drugs Revenue YoY (2017-2028) & (US$ Million) Figure 21. Latin America Recombinant Protein Drugs Sales YoY (2017-2028) & (K Doses) Figure 22. Latin America Recombinant Protein Drugs Revenue YoY (2017-2028) & (US$ Million) Figure 23. Middle East & Africa Recombinant Protein Drugs Sales YoY (2017-2028) & (K Doses) Figure 24. Middle East & Africa Recombinant Protein Drugs Revenue YoY (2017-2028) & (US$ Million) Figure 25. The Recombinant Protein Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021 Figure 26. The Top 5 and 10 Largest Manufacturers of Recombinant Protein Drugs in the World: Market Share by Recombinant Protein Drugs Revenue in 2021 Figure 27. Global Recombinant Protein Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021 Figure 28. Global Recombinant Protein Drugs Sales Market Share by Type (2017-2028) Figure 29. Global Recombinant Protein Drugs Revenue Market Share by Type (2017-2028) Figure 30. Global Recombinant Protein Drugs Sales Market Share by Application (2017-2028) Figure 31. Global Recombinant Protein Drugs Revenue Market Share by Application (2017-2028) Figure 32. North America Recombinant Protein Drugs Sales Market Share by Type (2017-2028) Figure 33. North America Recombinant Protein Drugs Revenue Market Share by Type (2017-2028) Figure 34. North America Recombinant Protein Drugs Sales Market Share by Application (2017-2028) Figure 35. North America Recombinant Protein Drugs Revenue Market Share by Application (2017-2028) Figure 36. North America Recombinant Protein Drugs Sales Share by Country (2017-2028) Figure 37. North America Recombinant Protein Drugs Revenue Share by Country (2017-2028) Figure 38. U.S. Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 39. Canada Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 40. Europe Recombinant Protein Drugs Sales Market Share by Type (2017-2028) Figure 41. Europe Recombinant Protein Drugs Revenue Market Share by Type (2017-2028) Figure 42. Europe Recombinant Protein Drugs Sales Market Share by Application (2017-2028) Figure 43. Europe Recombinant Protein Drugs Revenue Market Share by Application (2017-2028) Figure 44. Europe Recombinant Protein Drugs Sales Share by Country (2017-2028) Figure 45. Europe Recombinant Protein Drugs Revenue Share by Country (2017-2028) Figure 46. Germany Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 47. France Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 48. U.K. Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 49. Italy Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 50. Russia Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 51. Asia Pacific Recombinant Protein Drugs Sales Market Share by Type (2017-2028) Figure 52. Asia Pacific Recombinant Protein Drugs Revenue Market Share by Type (2017-2028) Figure 53. Asia Pacific Recombinant Protein Drugs Sales Market Share by Application (2017-2028) Figure 54. Asia Pacific Recombinant Protein Drugs Revenue Market Share by Application (2017-2028) Figure 55. Asia Pacific Recombinant Protein Drugs Sales Share by Region (2017-2028) Figure 56. Asia Pacific Recombinant Protein Drugs Revenue Share by Region (2017-2028) Figure 57. China Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 58. Japan Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 59. South Korea Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 60. India Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 61. Australia Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 62. Taiwan Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 63. Indonesia Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 64. Thailand Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 65. Malaysia Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 66. Philippines Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 67. Latin America Recombinant Protein Drugs Sales Market Share by Type (2017-2028) Figure 68. Latin America Recombinant Protein Drugs Revenue Market Share by Type (2017-2028) Figure 69. Latin America Recombinant Protein Drugs Sales Market Share by Application (2017-2028) Figure 70. Latin America Recombinant Protein Drugs Revenue Market Share by Application (2017-2028) Figure 71. Latin America Recombinant Protein Drugs Sales Share by Country (2017-2028) Figure 72. Latin America Recombinant Protein Drugs Revenue Share by Country (2017-2028) Figure 73. Mexico Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 74. Brazil Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 75. Argentina Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 76. Middle East and Africa Recombinant Protein Drugs Sales Market Share by Type (2017-2028) Figure 77. Middle East and Africa Recombinant Protein Drugs Revenue Market Share by Type (2017-2028) Figure 78. Middle East and Africa Recombinant Protein Drugs Sales Market Share by Application (2017-2028) Figure 79. Middle East and Africa Recombinant Protein Drugs Revenue Market Share by Application (2017-2028) Figure 80. Middle East and Africa Recombinant Protein Drugs Sales Share by Country (2017-2028) Figure 81. Middle East and Africa Recombinant Protein Drugs Revenue Share by Country (2017-2028) Figure 82. Turkey Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 83. Saudi Arabia Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 84. U.A.E Recombinant Protein Drugs Revenue (2017-2028) & (US$ Million) Figure 85. Recombinant Protein Drugs Value Chain Figure 86. Recombinant Protein Drugs Production Process Figure 87. Channels of Distribution Figure 88. Distributors Profiles Figure 89. Bottom-up and Top-down Approaches for This Report Figure 90. Data Triangulation Figure 91. Key Executives Interviewed